Pranlukast is an orally bioavailable cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50s = 4.3-7.2 nM in radioligand binding assays).1 It is selective for the CysLT1 receptor over the CysLT2 receptor (IC50 = 3,620 nM for the human receptor).2 Pranlukast inhibits mucus secretion induced by leukotriene D4 in isolated guinea pig trachea with an IC50 value of 0.3 ?M.3 It inhibits TNF-α-induced NF-?B p65 nuclear localization in U937 and Jurkat cells when used at concentrations of 10 and 100 ?M.4 Pranlukast inhibits bronchoconstriction induced by LTC4 , LTD4, and LTE4 , but not LTB4 , in guinea pigs (ID50s = 0.8, 1, 0.7, and >500 ?g/kg, respectively).5 It reduces cortical infarct volume by 81.6% and decreases neuronal death in the cortex, hippocampus, and striatum in a rat model of ischemia induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 0.03 mg/kg.6
1.Lynch, K.R., O'Neill, G.P., Liu, Q., et al.Characterization of the human cysteinyl leukotriene CysLT1 receptorNature399(6738)789-793(1999) 2.Heise, C.E., O'Dowd, B.F., Figueroa, D.J., et al.Characterization of the human cysteinyl leukotriene 2 receptorJ. Biol. Chem.275(39)30531-30536(2000) 3.Liu, Y.-C., Khawaja, A.M., and Rogers, D.F.Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitroBr. J. Pharmacol.124(3)563-571(1998) 4.Ichiyama, T., Hasegawa, S., Umeda, M., et al.Pranlukast inhibits NF-KB activation in human monocytes/macrophages and T cellsClin. Exp. Allergy33(6)802-807(2003) 5.Nakai, H., Konno, M., Kosuge, S., et al.New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationshipsJ. Med. Chem.31(1)84-91(1988) 6.Zhang, W.-P., Wei, E.-Q., Mei, R.-H., et al.Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in ratsActa Pharmacol. Sin.23(10)871-877(2002)
















